You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses

    SBC: PROFUSA, INC.            Topic: ST18C004

    The use of continuous glucose monitors can be an invaluable management tool for patients afflicted by glycemic variability due to critical illness or trauma. Maintaining stable glucose levels enhances health and lowers care costs, and individuals equipped with continuous glucose data have significantly improved outcomes. Profusa has developed highly miniaturized, injectable, tissue-like, glucose s ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  2. Visual Relative Navigation via Intelligent Ephemeral Relationships (VRNIER)

    SBC: TOYON RESEARCH CORPORATION            Topic: ST18C006

    As unmanned aircraft systems (UAS) become more prevalent there is an increasing desire to automate UAS navigation and control. To enable future UASs to perform a wider variety of missions, the they must be able to complete autonomous relative navigation to accomplish missions. Current technologies rely heavily on GPS measurements, which are undesirable since GPS signals may be unavailable in many ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  3. Pathogen Classification Tool (PaCT)

    SBC: Stottler Henke Associates, Inc.            Topic: ST18C002

    Stottler Henke proposes PaCT, leveraging our related past work in computer vision and machine learning. Drawing from techniques used in ExPATSS, a Phase II SBIR effort slated for transition to the Naval fleet, PaCT will perform bacterial characterization using features derived from the phenotype of the bacteria. PaCT will predict bacterial characteristics such as pathogenicity, antibiotic resistan ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  4. Human Performance Optimization: Ketone Esters for Optimization of Operator Performance in Hypoxia

    SBC: HVMN Inc.            Topic: SOCOM17C001

    In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  5. System for Nighttime and Low-Light Face Recognition

    SBC: Polaris Sensor Technologies, Inc.            Topic: SOCOM18A001

    The objective of this proposal is to develop instrumentation and algorithms for acquiring facial features for facial recognition in low- and no-light conditions.We will use cross-spectrum matching by exploiting infrared polarimetric imagery which tends to show features that match more closely visible imagery than conventional infrared.In addition to thermal infrared, we will also test subjects in ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  6. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Hybrid DNN-based Transfer Learning and CNN-based Supervised Learning for Object Recognition in Multi-modal Infrared Imagery

    SBC: TOYON RESEARCH CORPORATION            Topic: 1

    On this effort Toyon Research Corp. and The Pennsylvania State University are developing deep learning-based algorithms for object recognition and new class discovery in look-down infrared (IR) imagery. Our approach involves the development of a hybrid classifier that exploits both transfer learning and semi-supervised paradigms in order to maintain good generalization accuracy, especially when li ...

    STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency
  10. Computational Biology Platform Technology for Cellular Reprogramming

    SBC: IREPROGRAM, LLC            Topic: ST17C001

    Methods for interconversion between cell types (cellular reprogramming) are currently discovered through resource intensive trial and error. Experiments may test a multitude of transcription factors to identify correct combinations that influence cell fate. In addition, reprogramming approaches commonly use stem cell intermediates such as induced pluripotent stem cells (iPSCs), which are generated ...

    STTR Phase I 2018 Department of DefenseDefense Advanced Research Projects Agency
US Flag An Official Website of the United States Government